Amgen (AMGN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AMGN Amgen

Watchlist

273.440
-1.370-0.50%

Close Jan 22 16:00 ET

274.480
+1.040+0.38%

Post 20:01 ET

146.98BMarket Cap34.92P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Wall Street Today: Does Anyone Have the Cash for Stargates
Kevin Travers16:05 ET
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Benzinga15:43 ET
DeCODE Genetics: Complete Recombination Map of the Human-genome, a Major Step in Genetics
PR Newswire11:00 ET
Live Stock: Stargate Rivals the Scale of the Manhattan Project, Musk Said it's a Pipe Dream
Kevin TraversJan 22 10:45 ET
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
Zacks Jan 22 08:00 ET
Wall Street Today: AI Domestic Investment News on the Way
Kevin TraversJan 21 16:42 ET

Comments

Stock_Drift

Jan 18 08:51

$GlaxoSmithKline (GSK.US)$ $Amgen (AMGN.US)$ $AstraZeneca (AZN.US)$

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

vampirekitty169

Dec 31, 2024 09:05

🚀🚀🚀

$Amgen (AMGN.US)$ Bought as soon as I got the news and it’s +3% within 10 minutes, looking good!

What's new: Latest stock news and analysis

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14, 2024 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...